Add preferred source Takara Holdings on the 23rd released its April-June 2026 earnings, which had been delayed amid questions over the accounting treatment at its U.S. subsidiary Takara Bio USA. An investigation involving outside lawyers found no intentional accounting fraud and concluded no prior-year restatement was necessary. April-June sales came to ¥103.2 billion (approximately $657.9…
